Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QGC001 in chronic heart failure with reduced left ventricular systolic function
NL-OMON46235Phase 2Active, not recruiting
- Sponsor
- European Drug Development Hub
- Start
- Nov 2017
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic heart failure (CHF) comparing QGC001 with Placebo (2 arms). Primary endpoints: Primary efficacy endpoint and Primary safety endpoint. Started Nov 2017; status: active, not recruiting.
02
Drugs
firibastat
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on NL-OMON46235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46235.